89Zr-PSMA-617 PET/CT May Reveal Local Recurrence of Prostate Cancer Unidentified by 68Ga-PSMA-11 PET/CT. (28th May 2022)

• Record Type: Journal Article
• Authors: Rosar, Florian; Bartholomä, Mark; Maus, Stephan; Privé, Bastiaan M.; Khreish, Fadi; Franssen, Gerben M.; Derks, Yvonne H.W.; Nagarajah, James; Ezziddin, Samer
• Is Part Of: Clinical nuclear medicine. Volume 47:Number 5(2022)
• Page Start: 435
• Page End: 436
• Publication Date: 2022-05-28
• Subjects: prostate cancer -- biochemical recurrence -- zirconium 89 -- PSMA PET/CT; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000004108
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract: For localization of biochemical recurrence of prostate cancer, 68 Ga-PSMA-11 PET/CT imaging was performed in a 66-year-old man with no suspicious findings at 1 hour p.i. Additional 89 Zr-PSMA-617 PET/CT revealed a small local recurrence in the prostate bed, facilitating consecutive local therapy. This interesting image points to the potential of PET/CT with 89 Zr-labeled PSMA ligands, for example, 89 Zr-PSMA-617, for identifying the source of biochemical recurrence despite otherwise negative imaging including conventional PSMA PET/CT.